ImetelChat

With these hires in addition to the recent hires, It appears to me that Geron is very serious and committed to developing MDS and probably other applications. Also, it appears there is much confidence in success with the level of people they are able to hire.

With these hires in addition to the recent hires, It appears to me that Geron is very serious and committed to developing MDS and probably other applications. Also, it appears there is much confidence in success with the level of people they are able to hire.

With these hires in addition to the recent hires, It appears to me that Geron is very serious and committed to developing MDS and probably other applications. Also, it appears there is much confidence in success with the level of people they are able to hire.

I am quite pleased to have heard Duarte’s very positive comments about their very strong pharm pipeline and his talking about how much of jnj growth comes from acquisitions and that they plan to continue to be quite aggressive in the acquisition area.

I think MTB did some work on his SA article as I am now able to post “replies”, but not new posts. I also can “like” posts and read new posts now. I am not a subscriber and have no plans to pay $ to become a subscriber.

I am reposting my correspondence as a reminder that we may hear some rumblings very soon.


Feb 23
Dr. Patnaik: Are there some encouraging results in this area? Dr. Jay

Patnaik, Mrinal S., M.B.B.S.
Feb 24

to me
I think we should hear more conclusively by the end of March 2017.

Thanks

Thanks, BP for your thoughts. I have all along felt there is a good chance for a six month (from the Sept review) review. I am interested in your comment that there is a rolling/ongoing review of each patient as they meet the time requirements. Where did you get that?

Thanks, Fishermangents. Thanks what I was thinking, but without the knowledge. It seems this drug treats one of the possible side affects of Imetelstat treatment and/or a symptom of MDS, but not the underlying MDS disease.

Where does this leave Geron/Imetelstat? Looks scary or don't I get it? Janssen's Eprex effective in late-stage MDS study Jun 11 2016, 08:58 ET | By: Douglas W. House, SA News Editor A Phase 3 clinical trial, EPOANE 3021, evaluating Janssen's (NYSE:JNJ) EPREX (epoetin alfa) for the treatment of anemi...